Hongming Pan
Nanjing Tech University(CN)Harbin Medical University(CN)Sir Run Run Shaw Hospital(CN)Third Affiliated Hospital of Harbin Medical University(CN)Zhejiang University(CN)Bohai University(CN)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial(2008)5,801 cited
- → Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment(2013)1,189 cited
- → p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents(2013)942 cited
- → Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial(2015)797 cited
- → Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial(2014)624 cited
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial